ICH Stability Guidelines Overview
What are the ICH stability guidelines?
The ICH stability guidelines are the Q1 series (Q1A(R2) to Q1E) plus Q5C for biotechnological/biological products. All of them are still the current Step 4 texts. ICH has a single consolidated ICH Q1 guideline in progress that, once adopted, "supersedes ICH Q1A-F and Q5C" [1]. ICH's work plan schedules its Step 4 adoption for November 2026.
Approach: I searched the ICH Quality guideline texts. I checked the status of the Q1 revision against the ICH Q1 Expert Working Group work plan on ich.org.
The current guidelines (Step 4)
| Guideline | Title | Current Step 4 date | What it covers |
|---|---|---|---|
| Q1A(R2) | Stability Testing of New Drug Substances and Products | 6 Feb 2003 | The parent guideline. It sets the core stability data package for registering new molecular entities in the EC, Japan and the US. It addresses climatic zones I and II only, and does not cover abridged applications, variations or clinical trial applications [2] |
| Q1B | Photostability Testing of New Drug Substances and Products | 6 Nov 1996 | An annex to Q1A on light testing. It sets two light-source options and a decision flow chart that goes from directly exposed product to immediate pack to marketing pack. Confirmatory exposure is "not less than 1.2 million lux hours" and "not less than 200 watt hours/square meter" near-UV [3] |
| Q1C | Stability Testing for New Dosage Forms | 6 Nov 1996 | An annex covering new dosage forms of an approved active (for example, oral to parenteral, or capsule to tablet). In justified cases a reduced database may be acceptable, e.g. 6 months accelerated plus 6 months long-term data [4] |
| Q1D | Bracketing and Matrixing Designs | 7 Feb 2002 | Reduced designs (testing only the extremes of strength or container size and fill, or a subset of samples at each time point). Every reduced design "should be justified". For drug substances, "matrixing is of limited utility and bracketing is generally not applicable" [5] |
| Q1E | Evaluation of Stability Data | 6 Feb 2003 | How to use the data to propose a retest period or shelf life: statistical approaches, batch poolability at a 0.25 significance level, and when and how far you can extrapolate beyond the long-term data [6] |
| Q5C | Stability Testing of Biotechnological/Biological Products | 30 Nov 1995 | An annex for well-characterised proteins and polypeptides (e.g. cytokines, insulins, monoclonal antibodies, protein vaccines). It does not cover antibiotics, allergenic extracts, heparins, vitamins, whole blood or cellular blood components. It requires real-time, real-condition data and a stability-indicating profile [7] |
Q1F (Stability Data Package for Registration Applications in Climatic Zones III and IV) appears in these texts only through its effect on Q1A(R2). Adopting it changed the intermediate condition to 30°C ± 2°C/65% RH ± 5% RH and added 30°C/65% RH as an alternative long-term condition [2].
Q1A(R2) core conditions (drug substance, general case)
| Study | Condition | Minimum data at submission |
|---|---|---|
| Long term | 25°C ± 2°C/60% RH ± 5% RH or 30°C ± 2°C/65% RH ± 5% RH | 12 months |
| Intermediate | 30°C ± 2°C/65% RH ± 5% RH (none if 30°C/65% RH is the long-term condition) | 6 months |
| Accelerated | 40°C ± 2°C/75% RH ± 5% RH | 6 months |
- Refrigerated products: long term at 5°C ± 3°C, accelerated at 25°C/60% RH.
- Frozen products: long term at -20°C ± 5°C.
- Below -20°C: handled case by case.
- Batches: long-term data should cover at least three primary batches [2].
The consolidated ICH Q1 revision
- Status: the draft "Stability Testing of Drug Substances and Drug Products" was endorsed at Step 2 on 11 April 2025 and released for public consultation [1].
- Wider scope than the current series:
- synthetic and biological products, including oligonucleotides, ADCs, vaccines, allergenics, and the drug part of drug-device combinations;
- generics, biosimilars and post-approval changes;
- all four climatic zones.
- Not covered: device constituent parts, radiopharmaceuticals and whole blood products.
- New topics: holding times for intermediates, short-term storage, in-use stability, and annexes on reduced designs, stability modelling and ATMPs [1].
- Timeline: public consultation ran April to September 2025. The work plan dated 11 February 2026 expects Step 3 sign-off and Step 4 adoption in November 2026, with training material in June 2027 (ICH Q1 EWG Work Plan).
Until Step 4 is reached and each region implements it, Q1A(R2) to Q1E and Q5C remain the operative ICH texts.
Which stability testing conditions should we use?
Which conditions you use depends on three things: how the product will be stored, what packaging it is in, and which climatic zones you are filing in. For a room-temperature product for the EU, US and Japan, the current ICH Q1A(R2) default is long-term 25°C ± 2°C/60% RH ± 5% RH or 30°C ± 2°C/65% RH ± 5% RH, accelerated 40°C ± 2°C/75% RH ± 5% RH, and intermediate 30°C/65% RH only if you chose 25°C/60% RH for long-term and accelerated testing shows "significant change". The guideline says the choice of long-term condition "is up to the applicant" [2].
Approach: I read the Q1A(R2) storage-condition sections and the Step 2 draft of the consolidated ICH Q1. Q1A(R2) addresses climatic zones I and II only [2], so for hotter or more humid markets I used the draft's zone table, which is not yet adopted.
Q1A(R2) conditions by storage case (drug substance and drug product)
| Case | Long term | Intermediate | Accelerated |
|---|---|---|---|
| General case | 25°C ± 2°C/60% RH ± 5% RH, or 30°C ± 2°C/65% RH ± 5% RH (12 months) | 30°C ± 2°C/65% RH ± 5% RH (6 months of a 12-month study); none if 30°C/65% RH is the long-term condition | 40°C ± 2°C/75% RH ± 5% RH (6 months) |
| Semi-permeable containers (aqueous products) | 25°C ± 2°C/40% RH ± 5% RH, or 30°C ± 2°C/35% RH ± 5% RH (12 months) | 30°C ± 2°C/65% RH ± 5% RH (6 months); none if 30°C/35% RH is the long-term condition | 40°C ± 2°C/not more than 25% RH (6 months) |
| Impermeable containers | Any controlled or ambient humidity | – | – |
| Refrigerator | 5°C ± 3°C (12 months) | – | 25°C ± 2°C/60% RH ± 5% RH (6 months) |
| Freezer | -20°C ± 5°C (12 months) | – | None. Instead, test one batch at a higher temperature (e.g. 5°C ± 3°C or 25°C ± 2°C) to cover excursions |
| Below -20°C | Case by case | – | – |
All rows are from [2].
Rules that change the design:
-
Batches and data at filing: long-term data should cover at least 12 months on at least three primary batches at submission. "Alternative storage conditions can be used if justified."
-
What triggers intermediate testing (drug product): any one of the following at accelerated conditions:
- a 5% change in assay;
- any degradant exceeding its acceptance criterion;
- failure of appearance, physical or functionality criteria;
- where relevant to the dosage form, failure of pH or of dissolution for 12 units.
For a drug substance, significant change means failing its specification.
-
Semi-permeable packs: a 5% water loss after the equivalent of 3 months at 40°C/NMT 25% RH is a significant change. Water loss alone does not trigger intermediate testing. You can test at a higher RH and convert using the water-loss ratios, e.g. 75% RH to 25% RH uses a ratio of 3.0.
-
Refrigerated products: what you do depends on when accelerated testing fails:
- Significant change between 3 and 6 months: base the shelf life on real-time long-term data.
- Significant change within the first 3 months: provide a discussion of excursions during shipping and handling.
-
Test frequency: long-term testing every 3 months in year 1, every 6 months in year 2, then annually. Accelerated testing needs at least 3 time points (e.g. 0, 3, 6 months). Intermediate testing needs at least 4 (e.g. 0, 6, 9, 12 months).
-
In-use testing: testing after constitution or dilution should run through the in-use period on primary batches [2].
-
Photostability: at least one primary batch should be tested to Q1B "if appropriate" [2].
Supplying hotter or humid markets (draft ICH Q1, Step 2, not yet adopted)
Table 3 of the draft sets long-term conditions by climatic zone. Accelerated is 40°C ± 2°C/75% RH ± 5% RH for every zone:
- I and II:
- Long term: 25°C/60% RH, with intermediate 30°C/65% RH or 30°C/75% RH.
- Or long term at 30°C/65% RH or 30°C/75% RH, with no intermediate.
- III: 30°C/35% RH, 30°C/65% RH or 30°C/75% RH.
- IVa: 30°C/65% RH or 30°C/75% RH.
- IVb: 30°C ± 2°C/75% RH ± 5% RH.
The draft notes that "specific regional requirements for more severe storage conditions may however apply." It also says testing at 30°C/75% RH "could be justified as it encompasses all climate zones." If the product fails at that condition, it suggests a zone-specific condition, a shorter shelf life, different packaging, or reformulation [1].
What this means in practice: for a global room-temperature product, 30°C/75% RH long-term plus 40°C/75% RH accelerated is the single design that the draft says covers every zone. If you file only in the ICH regions, the Q1A(R2) general case applies. For proteins and other biologics, Q5C applies instead. It requires real-time data under real storage conditions [7].
If you tell me the dosage form, packaging and target markets, I can narrow this to one protocol.
Is the revised stability guideline final yet?
No. As far as I could find, the consolidated ICH Q1 ("Stability Testing of Drug Substances and Drug Products") has not reached Step 4. The latest text is still the Step 2 draft endorsed on 11 April 2025, which once adopted "supersedes ICH Q1A-F and Q5C" [1]. ICH plans to adopt it in November 2026, so final adoption is only weeks away.
Approach: I searched the ICH Quality guideline texts and ICH's own document database for a Step 4 Q1 text, and read the latest Q1 Expert Working Group work plan. ICH's news and Quality Guidelines pages would not load, so I couldn't read the Assembly outcome announcements directly.
Where it stands, from the Q1 EWG work plan dated 11 February 2026 (ICH Q1 EWG Work Plan):
| Date | Milestone |
|---|---|
| Nov 2022 | Concept paper and business plan endorsed; working group set up |
| Feb 2025 | Title changed to "ICH Q1 Stability Testing of Drug Substances and Drug Products" |
| Apr 2025 | Step 1 sign-off and Step 2a/b endorsement |
| Apr–Sep 2025 | Public consultation |
| Jul 2025–Sep 2026 | Revisions to resolve the consultation comments |
| Sept 2026 (planned) | Plenary Working Party engagement ahead of Step 3 sign-off |
| Nov 2026 (planned) | Step 3 sign-off and Step 4 adoption, with the Step 4 presentation |
| Jun 2027 (planned) | Training material delivered |
I found no Step 4 Q1 document on ICH's database. The current Q1A(R2), Q1B, Q1C, Q1D, Q1E and Q5C texts are still the Step 4 guidelines in force.
Practical point: even after ICH adopts it at Step 4, each regulator (EMA, the FDA, PMDA, MHRA and others) still has to implement it under its own procedure and effective date. Stability protocols filed now should still follow Q1A(R2) to Q1E and Q5C.
Sources: